PRESSEMITTEILUNGEN

(pressebox) Konstanz, 26.10.2009,

The companies Nycomed and Trenzyme, both situated in Konstanz, extended their cooperation agreement for another four years.

As a service provider for Nycomed, Trenzyme will continue handling projects ranging from DNA cloning, recombinant expression in E.coli, yeast and mammalian cells to protein purification and cell line development. Concomitantly Trenzyme will remain in the premises on the Nycomed campus.

By continuing the cooperation, Nycomed maintains the status of a preferred client. In return, Trenzyme maintains the status of a preferred service provider for Nycomed. Both parties agreed that the past cooperation was fruitful and beneficial for both sides. The geographical proximity of the two companies allows also greater flexibility in responding to the scientific demands of projects and is thus considered as an important factor for the success of this cooperation. Therefore at Nycomed efforts are being made to provide Trenzyme with its growing need for space on the Nycomed campus.

Both parties maintain silence over the volume of the cooperation agreement.

Nycomed is a privately owned global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio.

Its R&D is built to be open for partnerships as in-licensing is a cornerstone of the company’s growth strategy.

Nycomed employs 12,000 associates worldwide, and its products are available in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS, and Latin America. While the US and Japan are commercialised through best-in-class partners, Nycomed will further strengthen its position in key Asian markets.

Headquartered in Zurich, Switzerland, the company generated in 2008 total sales of ? 3.4 billion and an adjusted EBITDA of ? 1.2 billion.

For more information visit www.nycomed.com

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Diese Pressemitteilung beobachten

Gerne informieren wir Sie per E-Mail, sobald inaktive Pressemitteilungen vom Herausgeber freigeschaltet werden. Beobachten Sie dazu die entsprechenden Meldungen:

Trackback URL

Asian Markets, Cis, Class Partners, Cooperation Agreement, Dna Cloning, E Coli, Geographical Proximity, Global Pharmaceutical Company, Growth Strategy, Inflammatory Diseases, Latin America, Mammalian Cells, Nycomed, Osteoporosis, Otc Products, Preferred Client, Preferred Service Provider, Protein Purification, Yeast Cells, Zurich Switzerland